statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for...

Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment

Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds PR Newswire NEW YORK, March 27, 2024...

Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Hoth Therapeutics announces positive preclinical research in Alzheimer's

Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's...

Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ

Hoth Therapeutics, Inc. (NASDAQ:HOTH  Get Free Report) was the recipient of a large decline in short interest during the month of February. As of February 29th, there was short interest...

Hoth Therapeutics, Inc. (NASDAQ:HOTH) Short Interest Down 9.9% in February

Hoth Therapeutics reveals preclinical findings on HT-ALZ, a potential Alzheimer's therapeutic targeting the Substance P/Neurokinin 1 Receptor pathway. HT-ALZ exhibits significant reductions in...

Why Is Alzheimer's-Focused Hoth Therapeutics Stock Trading Higher On Tuesday?

Hoth Therapeutics Retains Venable LLP to Expand Its Patent Portfolio Hoth Therapeutics Retains Venable LLP to Expand Its Patent Portfolio PR Newswire NEW YORK, Feb. 29, 2024 NEW YORK, Feb. 29, 2024...

Hoth Therapeutics Retains Venable LLP to Expand Its Patent Portfolio

Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic...

Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic

Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024 Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024 PR Newswire NEW YORK, Feb. 13, 2024...

Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024

Hoth Therapeutics, Inc. (NASDAQ:HOTH  Free Report)  Analysts at HC Wainwright issued their FY2023 earnings per share (EPS) estimates for Hoth Therapeutics in a report issued on Monday...

HC Wainwright Comments on Hoth Therapeutics, Inc.'s FY2023 Earnings (NASDAQ:HOTH)

Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in New York, NY.

Volume	48,634.00
52-Wk High	$4.30
52-Wk Low	$0.99

HOTH Hoth Therapeutics Inc

About

Feed

News

Fundamentals